Article

Exploring New Treatment Options In HCC

Author(s):

This Onclive® webinar will focus on best practices and multidisciplinary approaches in the management of hepatocellular carcinoma and the impact of the COVID-19 pandemic on treatment selection in patients with HCC. Join us Thursday, June 23, 2020 at 8 PM EST.

Date/Time: Tuesday, June 23, 2020 at 8 PM EST

This OncLive® webinar will focus on best practices and multidisciplinary approaches in the management of hepatocellular carcinoma and the impact of the COVID-19 pandemic on treatment selection in patients with HCC.

Click here to register today!

The following topics will be discussed:

  • Impact of the COVID pandemic on reentry and reopening
  • Selection of therapy during the pandemic, oral versus IV therapies and immunotherapy
  • Recent approval of atezolizumab + bevacizumab and how this will impact the treatment landscape of HCC

Associate Professor of Clinical Medicine; Medical Director of Clinical Investigations Support Office; Phase I program director, USC Norris Comprehensive Cancer Center, Los Angeles, CA

Amit G. Singal, MD, David Bruton Jr. Professor in Clinical Cancer Research; Associate Professor of Medicine; Medical Director of Liver Tumor Program; Clinical Chief of Hepatology, University of Texas Southwestern, Dallas, TX

Catherine T. Frenette, MD, Director of Gastroenterology, Transplant Hepatology, MD Anderson Cancer Center, La Jolla,CA

Sponsored By:

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related Videos
Richard T. Lee, MD, Cherng Family Director’s Chair, Center for Integrative Oncology, medical director, clinical professor, Supportive & Integrative Medicine, Department of Supportive Care Medicine, City of Hope
Rachna T. Shroff, MD, MS
Daneng Li, MD, associate professor, Department of Medical Oncology & Therapeutics Research, and co-director, Neuroendocrine Tumor Program, City of Hope
Dr Janjigian on 5-Year Data With Nivolumab Plus Chemotherapy in Gastric/GEJ/Esophageal Cancer
Susumu Hijioka, MD, PhD
Kanwal PS Raghav, MBBS, MD
Vikas S. Ostwal, MD
Dr Shreenivas on the Association Between MUC1 and CLDN18 in GI Cancers
Dr Strosberg on Cabozantinib vs Placebo in Patients With Advanced GI NETs
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center